Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer



Status:Active, not recruiting
Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:2/17/2019
Start Date:January 6, 2011

Use our guide to learn which trials are right for you!

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

This randomized phase III clinical trial studies chemotherapy with or without trastuzumab
after surgery to see how well they work in treating women with invasive breast cancer. Drugs
used in chemotherapy work in different ways to stop the growth of tumor cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving
more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill
more tumor cells. Monoclonal antibodies, such as trastuzumab, can block cancer growth in
different ways. Some block the ability of tumor cells to grow and spread. Others find tumor
cells and help kill them or carry tumor-killing substances to them. It is not yet known
whether combination chemotherapy is more effective with trastuzumab in treating breast
cancer.

PRIMARY OBJECTIVES:

I. To determine whether the addition of trastuzumab to chemotherapy (TC or AC→WP) improves
invasive disease-free survival (IDFS) in women with resected node-positive or high-risk
node-negative breast cancer which is reported as human epidermal growth factor receptor
(HER)2-low by all HER2 testing performed.

SECONDARY OBJECTIVES:

I. To determine whether the addition of trastuzumab to chemotherapy (TC or AC→WP) improves
disease-free survival (DFS)-ductal carcinoma in situ (DCIS) in women with resected
node-positive or high-risk node-negative breast cancer which is reported as HER2-low by all
HER2 testing performed.

II. To determine whether the addition of trastuzumab to chemotherapy (TC or AC→WP) improves
breast cancer-free survival (BCFS) in women with resected node-positive or high-risk
node-negative breast cancer which is reported as HER2-low by all HER2 testing performed.

III. To determine whether the addition of trastuzumab to chemotherapy (TC or AC→WP) improves
recurrence-free interval (RFI) in women with resected node-positive or high-risk
node-negative breast cancer which is reported as HER2-low by all HER2 testing performed.

IV. To determine whether the addition of trastuzumab to chemotherapy (TC or AC→WP) improves
distant recurrence-free interval (DRFI) in women with resected node-positive or high-risk
node-negative breast cancer which is reported as HER2-low by all HER2 testing performed.

V. To determine whether the addition of trastuzumab to chemotherapy (TC or AC→WP) improves
overall survival (OS) in women with resected node-positive or high-risk node-negative breast
cancer which is reported as HER2-low by all HER2 testing performed.

VI. To evaluate the associations between amenorrhea and circulating reproductive hormone
levels, and the associations between chemotherapy regimen, amenorrhea, and IDFS benefit in
premenopausal women eligible at baseline for the menstrual history assessments.

VII. To evaluate the toxicity associated with each of the regimens. VIII. To test the
hypothesis that the HER2 messenger ribonucleic acid (mRNA) level is the predictor of the
degree of benefit from trastuzumab and the threshold for benefit in the adjuvant setting is
lower than defined by current American Society of Clinical Oncology (ASCO)/College of
American Pathologists (CAP) Guidelines for HER2 assays (immunohistochemistry [IHC] and
fluorescent in situ hybridization [FISH]).

IX. To identify and/or validate molecular predictors of the degree of benefit from the
addition of trastuzumab to chemotherapy (TC or AC→WP).

X. To test the alternative hypothesis that the main determinant of trastuzumab response in
the adjuvant setting of HER2-low breast cancer is through antibody-dependent cellular
cytotoxicity (ADCC) by demonstrating that the polymorphism of the Fcgamma receptor gene is
predictive of the degree of benefit from the addition of trastuzumab to chemotherapy (TC or
AC→WP).

XI. To examine the relationship between behavioral host factors (obesity, tobacco, alcohol)
and comorbid conditions that may influence systemic inflammation and breast cancer outcomes,
controlling for tumor/stage characteristics and treatment assignment.

XII. To examine the relationship between medication exposures that may influence systemic
inflammation and breast cancer outcomes, controlling for tumor/stage characteristics and
treatment assignment.

XIII. To examine the relationship between comorbid conditions, medication exposures, and
behavioral host factors together and breast cancer outcomes, controlling for tumor/stage
characteristics and treatment assignment.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

NOTE: *Chemotherapy regimen is based on the investigator's preference.

ARM I:

GROUP A: Patients receive docetaxel intravenously (IV) over 60 minutes and cyclophosphamide
IV over 30 minutes on day 1. Treatment repeats every 3 weeks for 6 courses.

GROUP B: Patients receive doxorubicin hydrochloride IV over 15 minutes and cyclophosphamide
IV over 30 minutes on day 1.

Treatment repeats every 2 or 3 weeks (at the investigator's discretion) for 4 courses.
Patients then receive paclitaxel IV over 60 minutes once weekly for 12 doses.

ARM II:

GROUP A: Patients receive chemotherapy as in Arm IA. Patients also receive trastuzumab IV
over 30-90 minutes on day 1. Trastuzumab treatment repeats every 3 weeks for 51 weeks.

GROUP B: Patients receive chemotherapy as in Arm IB. Patients also receive paclitaxel IV over
60 minutes weekly and trastuzumab IV over 30-90 minutes weekly for 12 doses. After completion
of paclitaxel, patients receive trastuzumab IV over 30-90 minutes on day 1. Treatment repeats
every 3 weeks for 13 courses.

After completion of study treatment, patients are followed up every 6 months for 5 years and
then every 12 months for 5 years.

Inclusion Criteria:

- Patients should have a life expectancy of at least 10 years, excluding their diagnosis
of breast cancer; (comorbid conditions should be taken into consideration, but not the
diagnosis of breast cancer)

- Women of reproductive potential must agree to use an effective non-hormonal method of
contraception (for example condoms, some intrauterine devices, diaphragms, tubal
ligation, vasectomized partner, or abstinence) during therapy and for at least 6
months (Arm 1 patients) and for at least 7 months (Arm 2 patients) after the last dose
of study therapy (chemotherapy or trastuzumab)

- Submission of tumor samples from the breast surgery is required for all patients;
therefore, the local pathology department policy regarding release of tumor samples
must be considered in the screening process; patients whose tumor samples are located
in a pathology department that by policy will not submit any samples for research
purposes should not be approached for participation in the B-47 trial

- The patient must have signed and dated an Institutional Review Board (IRB)-approved
consent form that conforms to federal and institutional guidelines

- Eastern Cooperation Oncology Group (ECOG) performance status of 0 or 1

- The tumor must be unilateral invasive adenocarcinoma of the breast on histologic
examination

- All of the following staging criteria (according to the 7th edition of the American
Joint Committee on Cancer [AJCC] Cancer Staging Manual) must be met:

- By pathologic evaluation, primary tumor must be pT1-3

- By pathologic evaluation, ipsilateral nodes must be pN0, pN1 (pN1mi, pN1a, pN1b,
pN1c), pN2a, pN2b, pN3a, or pN3b

- If pN0, one of the following criteria must be met:

- pT2 and estrogen receptor (ER) negative and progesterone receptor (PgR)
negative; or

- pT2 and ER positive (PgR status may be positive or negative) and either
grade 3 histology or Oncotype DX Recurrence Score of >= 25; or

- pT3 regardless of hormone receptor status, histologic grade, and
Oncotype DX Recurrence Score

- HER2 status of the primary tumor must be evaluated prior to randomization; all testing
performed must indicate that the tumor is HER2-low as defined below

- IHC must be performed and the IHC staining results must indicate a score of 1+
(in situ hybridization [ISH] testing is not required) or 2+ (ISH must also be
performed and must indicate that the tumor is HER2-low as described below)

- If ISH testing is performed, test results must be as follows and IHC must be 1+
or 2+: the ratio of HER2 to chromosome enumeration probe 17 (CEP17) must be < 2.0
or, if a ratio was not performed, the HER2 gene copy number must be < 4 per
nucleus

- Note: If the IHC staining intensity is reported as a range, e.g., 0 to 1+ or 1+
to 2+, the higher intensity score in the range should be used to determine
eligibility

- The patient must have undergone either a total mastectomy or breast-conserving surgery
(lumpectomy); (patients who have had a nipple-sparing mastectomy are eligible)

- For patients who undergo lumpectomy, the margins of the resected specimen must be
histologically free of invasive tumor and ductal carcinoma in situ (DCIS) as
determined by the local pathologist; if pathologic examination demonstrates tumor at
the line of resection, additional operative procedures may be performed to obtain
clear margins; if tumor is still present at the resected margin after re-excision(s),
the patient must undergo total mastectomy to be eligible; (patients with margins
positive for lobular carcinoma in situ [LCIS] are eligible without additional
resection)

- For patients who undergo mastectomy, margins must be free of gross residual tumor;
(patients with microscopic positive margins are eligible as long as post-mastectomy
radiation therapy [RT] of the chest wall will be administered)

- The patient must have completed one of the procedures for evaluation of pathologic
nodal status listed below:

- Sentinel lymphadenectomy alone:

- If pathologic nodal staging based on sentinel lymphadenectomy is pN0 or pN1b

- If pathologic nodal staging based on sentinel lymphadenectomy is pN1mi or
pN1a, the primary tumor must be T1 or T2 by pathologic evaluation and the
nodal involvement must be limited to 1 or 2 positive nodes

- Sentinel lymphadenectomy followed by removal of additional non-sentinel lymph
nodes if the sentinel node (SN) is positive; or

- Axillary lymphadenectomy with or without SN isolation procedures

- The interval between the last surgery for breast cancer (treatment or staging) and
randomization must be no more than 84 days

- The patient must have ER analysis performed on the primary tumor prior to
randomization; if ER analysis is negative, then PgR analysis must also be performed
(either the core biopsy or surgical resection specimen can be used for ER/PgR
testing); patients with a primary tumor that is hormone receptor-positive or
receptor-negative are eligible

- Absolute neutrophil count (ANC) must be >= 1,200/mm^3

- Platelet count must be >= 100,000/mm^3

- Hemoglobin must be >= 10 g/dL

- Total bilirubin must be =< upper limit of normal (ULN) for the lab unless the patient
has a bilirubin elevation > ULN to 1.5 x ULN due to Gilbert disease or similar
syndrome involving slow conjugation of bilirubin

- Alkaline phosphatase must be =< 2.5 x ULN for the lab

- Aspartate aminotransferase (AST) must be =< 1.5 x ULN for the lab (if alanine
aminotransferase [ALT] is performed instead of AST [per institution's standard
practice], the alanine aminotransferase [ALT] value must be =< 1.5 x ULN; if both were
performed, the AST must be =< 1.5 x ULN)

- Alkaline phosphatase and AST may not both be > the ULN

- Patients with AST or alkaline phosphatase > ULN are eligible for inclusion in the
study if liver imaging (computed tomography [CT], magnetic resonance imaging [MRI],
positron emission tomography [PET]-CT, or PET scan) performed within 90 days prior to
randomization does not demonstrate metastatic disease and the above requirements are
met

- Patients with alkaline phosphatase that is > ULN but =< 2.5 x ULN or unexplained bone
pain are eligible for inclusion in the study if a bone scan, PET-CT scan, or PET scan
performed within 90 days prior to randomization does not demonstrate metastatic
disease

- The most recent postoperative serum creatinine performed within 6 weeks prior to
randomization must be =< ULN for the lab

- Left ventricular ejection fraction (LVEF) assessment must be performed within 90 days
prior to randomization; LVEF assessment performed by 2-dimensional (D) echocardiogram
is preferred, however, multi-gated acquisition (MUGA) scan maybe substituted based on
institutional preferences

- For patients who will receive the TC chemotherapy regimen, the LVEF must be >=
50% regardless of the cardiac imaging facility's lower limit of normal

- For patients who will receive the AC-->WP chemotherapy regimen, the LVEF must be
>= 55% regardless of the cardiac imaging facility's lower limit of normal

- NOTE: Since the pre-entry LVEF serves as the baseline for comparing subsequent
LVEF assessments, it is critical that this baseline study be an accurate
assessment; if the baseline LVEF is > 70%, the investigator is encouraged to have
the accuracy of the initial LVEF result confirmed and repeat the test if the
accuracy is uncertain

Exclusion Criteria:

- Primary tumor with any of the following HER2 testing results:

- IHC staining intensity:

- 0 on all evaluations of specimens

- 3+ on evaluation of any specimen

- ISH with a ratio of HER2 to CEP17 >= 2.0 on evaluation of any specimen

- ISH result indicating HER2 gene copy number >= 4 per nucleus on evaluation of any
specimen

- T4 tumors including inflammatory breast cancer

- Definitive clinical or radiologic evidence of metastatic disease

- NOTE: Chest imaging (mandatory for all patients) and other imaging (if required)
must have been performed within 90 days prior to randomization

- Synchronous or previous contralateral invasive breast cancer (patients with
synchronous and/or previous contralateral DCIS or LCIS are eligible)

- Any previous history of ipsilateral invasive breast cancer or ipsilateral DCIS;
(patients with synchronous or previous ipsilateral LCIS are eligible)

- History of non-breast malignancies (except for in situ cancers treated only by local
excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior
to randomization

- Previous therapy with anthracyclines, taxanes, or trastuzumab for any malignancy

- Chemotherapy or HER2-targeted therapy administered for the currently diagnosed breast
cancer prior to randomization

- Whole-breast RT prior to randomization or partial-breast RT that cannot be completed
on or before the date of randomization

- Continued endocrine therapy such as raloxifene or tamoxifen (or other selective
estrogen receptor modulator [SERM]) or an aromatase inhibitor; patients are eligible
if these medications are discontinued prior to randomization

- Any continued use of sex hormonal therapy, e.g., birth control pills, ovarian hormone
replacement therapy; patients are eligible if these medications are discontinued prior
to randomization

- Cardiac disease (history of and/or active disease) that would preclude the use of the
drugs included in the treatment regimens; this includes but is not confined to:

- Active cardiac disease:

- Angina pectoris that requires the current use of anti-anginal medication

- Ventricular arrhythmias except for benign premature ventricular contractions

- Supraventricular and nodal arrhythmias requiring a pacemaker or not
controlled with medication

- Conduction abnormality requiring a pacemaker

- Valvular disease with documented compromise in cardiac function

- Symptomatic pericarditis

- History of cardiac disease:

- Myocardial infarction documented by elevated cardiac enzymes or persistent
regional wall abnormalities on assessment of left ventricle (LV) function

- History of documented congestive heart failure (CHF)

- Documented cardiomyopathy

- Hypertension defined according to the following ineligibility criteria:

- For patients who will receive TC (regardless of the patient's age): uncontrolled
hypertension defined as sustained systolic blood pressure (BP) > 150 mm Hg or
diastolic BP > 90 mm Hg; (patients with initial BP elevations are eligible if
initiation or adjustment of BP medication lowers pressure to meet entry criteria)

- For patients < 50 years old who will receive AC-->WP: uncontrolled hypertension
defined as sustained systolic BP > 150 mm Hg or diastolic BP > 90 mm Hg; patients
with initial BP elevations are eligible if initiation or adjustment of BP
medication lowers pressure to meet entry criteria

- For patients >= 50 years old who will receive AC-->WP:

- Uncontrolled hypertension defined as sustained systolic BP > 150 mm Hg or
diastolic BP > 90 mm Hg

- Controlled hypertension (systolic BP =< 150 mm Hg and diastolic BP =< 90
mmHg), if anti-hypertensive medication(s) are needed

- NOTE: Patients who are not eligible based on the AC-WP regimen BP criteria but
who meet the TC regimen BP criteria are eligible for B-47, if the intended
chemotherapy regimen is changed to TC

- Active hepatitis B or hepatitis C with abnormal liver function tests

- Intrinsic lung disease resulting in dyspnea

- Poorly controlled diabetes mellitus

- Active infection or chronic infection requiring chronic suppressive antibiotics

- Nervous system disorder (paresthesia, peripheral motor neuropathy, or peripheral
sensory neuropathy) >= grade 2, per the Common Terminology Criteria for Adverse Events
(CTCAE) version (v)4.0

- Conditions that would prohibit administration of corticosteroids

- Chronic daily treatment with corticosteroids with a dose of >= 10 mg/day
methylprednisol one equivalent (excluding inhaled steroids)

- Known hypersensitivity to any of the study drugs or excipients, e.g., polysorbate 80
and Cremophor EL

- Pregnancy or lactation at the time of study entry; (Note: pregnancy testing must be
performed within 2 weeks prior to randomization according to institutional standards
for women of childbearing potential)

- Other non-malignant systemic disease that would preclude the patient from receiving
study treatment or would prevent required follow-up

- Psychiatric or addictive disorders or other conditions that, in the opinion of the
investigator, would preclude the patient from meeting the study requirements

- Use of any investigational product within 30 days prior to randomization
We found this trial at
1278
sites
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
(207) 621-6100
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
?
mi
from
Augusta, ME
Click here to add this to my saved trials
8600 Old Georgetown Road
Bethesda, Maryland 20814
301-896-3100
Suburban Hospital Suburban Hospital is a community-based, not-for-profit hospital serving Montgomery County and the surrounding...
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
(484) 884-2200
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
800 Washington St
Boston, Massachusetts 02111
(617) 636-5000
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
?
mi
from
Boston, MA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1 South Prospect Street
Burlington, Vermont 05401
802-656-8990
?
mi
from
Burlington, VT
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
(954) 771-8000
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
(409) 772-1011
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
?
mi
from
Galveston, TX
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
Jupiter, Florida 33458
?
mi
from
Jupiter, FL
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
(269) 341-7654
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
(702) 383-2000
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
(501) 686-7000
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
777 Hemlock Street
Macon, Georgia 31201
(478) 633-1000
Medical Center of Central Georgia Navicent Health is a designated Level I Trauma Center and...
?
mi
from
Macon, GA
Click here to add this to my saved trials
300 Community Drive
Manhasset, New York 11030
(516) 562-0100
North Shore University Hospital North Shore-LIJ Health System includes 16 award-winning hospitals and nearly 400...
?
mi
from
Manhasset, NY
Click here to add this to my saved trials
433 Southwest 10th Street
Ocala, Florida 34471
?
mi
from
Ocala, FL
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
593 Eddy Street
Providence, Rhode Island 02903
401-444-4000
Rhode Island Hospital Founded in 1863, Rhode Island Hospital in Providence, RI, is a private,...
?
mi
from
Providence, RI
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
60 Crittenden Blvd # 70
Rochester, New York 14642
(585) 275-2121
University of Rochester The University of Rochester is one of the country's top-tier research universities....
?
mi
from
Rochester, NY
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
(210) 567-7000
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
(206) 667-5000
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
3900 W Avera Drive
Sioux Falls, South Dakota 57108
(605) 322-4700
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
601 South Sherman Street
Spokane, Washington 99202
(509) 228-1000
Cancer Care Northwest - Spokane South Cancer Care Northwest is the Inland Northwest’s premier cancer...
?
mi
from
Spokane, WA
Click here to add this to my saved trials
808 North 39th Avenue
Yakima, Washington 98902
?
mi
from
Yakima, WA
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
Aberdeen, South Dakota 57401
?
mi
from
Aberdeen, SD
Click here to add this to my saved trials
Abilene, Texas 79601
?
mi
from
Abilene, TX
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
818 Riverside Ave.
Adrian, Michigan 49221
(517) 265-0900
Bixby Medical Center ProMedica's Mission is to improve your health and well-being. Which is why,...
?
mi
from
Adrian, MI
Click here to add this to my saved trials
Adrian, Michigan 49221
?
mi
from
Adrian, MI
Click here to add this to my saved trials
?
mi
from
Akron, OH
Click here to add this to my saved trials
Albany, Georgia 31701
?
mi
from
Albany, GA
Click here to add this to my saved trials
?
mi
from
Albany, NY
Click here to add this to my saved trials
?
mi
from
Albany, NY
Click here to add this to my saved trials
315 South Manning Boulevard
Albany, New York 12208
?
mi
from
Albany, NY
Click here to add this to my saved trials
Albuquerque, New Mexico 87106
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Albuquerque, New Mexico 87110
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Alexandria, Louisiana 71301
?
mi
from
Alexandria, LA
Click here to add this to my saved trials
Alexandria, Minnesota 56308
?
mi
from
Alexandria, MN
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Altamonte Springs, Florida 32701
?
mi
from
Altamonte Springs, FL
Click here to add this to my saved trials
Alton, Illinois 62002
?
mi
from
Alton, IL
Click here to add this to my saved trials
Amarillo, Texas 79106
?
mi
from
Amarillo, TX
Click here to add this to my saved trials
170 North 1100 East
American Fork, Utah 84003
?
mi
from
American Fork, UT
Click here to add this to my saved trials
Ames, Iowa 50010
?
mi
from
Ames, IA
Click here to add this to my saved trials
Ames, Iowa 50010
?
mi
from
Ames, IA
Click here to add this to my saved trials
?
mi
from
Amsterdam, NY
Click here to add this to my saved trials
Anacortes, Washington 98221
?
mi
from
Anacortes, WA
Click here to add this to my saved trials
Anaheim, California 92806
?
mi
from
Anaheim, CA
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
?
mi
from
Anderson, IN
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
(864) 512-4640
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
?
mi
from
Anderson, SC
Click here to add this to my saved trials
Anderson, South Carolina 29621
?
mi
from
Anderson, SC
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Ann Arbor, Michigan 48106
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Annapolis, Maryland 21401
?
mi
from
Annapolis, MD
Click here to add this to my saved trials
?
mi
from
Anniston, AL
Click here to add this to my saved trials
Antigo, Wisconsin 54409
?
mi
from
Antigo, WI
Click here to add this to my saved trials
?
mi
from
Antioch, CA
Click here to add this to my saved trials
?
mi
from
Appleton, WI
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
?
mi
from
Arroyo Grande, CA
Click here to add this to my saved trials
364 White Oak St
Asheboro, North Carolina 27203
(336) 625-5151
Randolph Hospital Since 1932, Randolph Hospital has been fortunate to employ dedicated and loyal personnel...
?
mi
from
Asheboro, NC
Click here to add this to my saved trials
Asheville, North Carolina 28801
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28816
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28801
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28801
?
mi
from
Asheville, NC
Click here to add this to my saved trials
Asheville, North Carolina 28803
?
mi
from
Asheville, NC
Click here to add this to my saved trials
?
mi
from
Athens, GA
Click here to add this to my saved trials
Atlanta, Georgia 30342
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
(404) 851-8000
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
1968 Peachtree Rd NW
Atlanta, Georgia 30309
(404) 605-5000
Piedmont Hospital For more than a century, Piedmont Healthcare has been a recognized leader in...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30303
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
(404) 686-4411
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Atlanta, Georgia 30342
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Attleboro, Massachusetts 02703
?
mi
from
Attleboro, MA
Click here to add this to my saved trials
Auburn, California 95602
?
mi
from
Auburn, CA
Click here to add this to my saved trials
?
mi
from
Auburn, CA
Click here to add this to my saved trials
?
mi
from
Auburn, NY
Click here to add this to my saved trials
Auburn, Washington 98001
?
mi
from
Auburn, WA
Click here to add this to my saved trials
Augusta, Georgia 30912
?
mi
from
Augusta, GA
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
(303) 695-2600
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
Austell, Georgia 30106
?
mi
from
Austell, GA
Click here to add this to my saved trials
Austin, Texas 78705
?
mi
from
Austin, TX
Click here to add this to my saved trials
?
mi
from
Austin, TX
Click here to add this to my saved trials
?
mi
from
Austin, TX
Click here to add this to my saved trials
Austin, Texas 78759
?
mi
from
Austin, TX
Click here to add this to my saved trials
1500 Red River Street
Austin, Texas 78701
?
mi
from
Austin, TX
Click here to add this to my saved trials